Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

被引：0
|
作者：
A F List
J M Bennett
M A Sekeres
B Skikne
T Fu
J M Shammo
S D Nimer
R D Knight
A Giagounidis
机构：
来源：
Leukemia | 2015年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Correction to: Leukemia (2014) 28, 1033–1040; doi:10.1038/leu.2013.305 Since the publication of this article it has been noted that there was an omission in the listing of conflict of interest. JM Bennett was listed as having no conflict of interest; however, the authors would like to correct this to read:
引用
收藏
页码：2452 / 2452
相关论文
共 50 条
  • [31] Increases In Mirna-145 and Mirna-146a Expression In Patients with IPSS Lower-Risk Myelodysplastic Syndromes and Del(5q) Treated with Lenalidomide
    Oliva, Esther Natalie
    Nobile, Francesco
    Iacopino, Pasquale
    Alimena, Giuliana
    Di Raimondo, Francesco
    Palumbo, Giuseppe A.
    Lagana, Carmelo
    D'Errigo, Maria Grazia
    Latagliata, Roberto
    Cuzzola, Maria
    BLOOD, 2010, 116 (21) : 1494 - 1494
  • [32] MODELLING THE LONG-TERM SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) DEL (5Q) TREATED WITH LENALIDOMIDE
    Benettaib, B.
    Lee, D.
    Dhanasiri, S.
    Brereton, N.
    HAEMATOLOGICA, 2013, 98 : 310 - 310
  • [33] Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)
    Follo, Matilde Y.
    Finelli, Carlo
    Clissa, Cristina
    Mongiorgi, Sara
    Baldazzi, Carmen
    Stanzani, Marta
    Baccarani, Michele
    Cocco, Lucia
    BLOOD, 2013, 122 (21)
  • [34] Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide
    Gerds, Aaron T.
    List, Alan F.
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Li, Jack Shiansong
    Swern, Arlene S.
    Sugrue, Mary M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [35] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
    Kuendgen, A.
    Lauseker, M.
    List, A. F.
    Fenaux, P.
    Giagounidis, A. A.
    Brandenburg, N. A.
    Backstrom, J.
    Glasmacher, A.
    Hasford, J.
    Germing, U.
    LEUKEMIA, 2013, 27 (05) : 1072 - 1079
  • [36] Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial
    Garcia-Manero, Guillermo
    Almeida, Antonio
    Fenaux, Pierre
    Gattermann, Norbert
    Giagounidis, Aristoteles
    Goldberg, Stuart L.
    Ozawa, Keiya
    Weaver, Jerry
    Santini, Valeria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 213 - +
  • [37] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
    A Kuendgen
    M Lauseker
    A F List
    P Fenaux
    A A Giagounidis
    N A Brandenburg
    J Backstrom
    A Glasmacher
    J Hasford
    U Germing
    Leukemia, 2013, 27 : 1072 - 1079
  • [38] IMPACT OF GENE MUTATIONS ON RESPONSE TO LENALIDOMIDE AND OS IN LOWER-RISK NON-DEL(5Q) MDS PATIENTS INELIGIBLE/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
    Santini, V.
    Fenaux, P.
    Giagounidis, A.
    Platzbecker, U.
    Almeida, A.
    List, A. F.
    Zhong, J.
    Wu, C.
    Mavrommatis, K.
    Beach, C. L.
    MacBeth, K. J.
    LEUKEMIA RESEARCH, 2017, 55 : S14 - S14
  • [39] IMPACT OF GENE MUTATIONS ON RESPONSE TO LENALIDOMIDE AND OS IN LOWER-RISK NON-DEL(5Q) MDS PATIENTS INELIGIBLE/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
    Santini, V.
    Fenaux, P.
    Giagounidis, A.
    Platzbecker, U.
    Almeida, A.
    List, A. F.
    Zhong, J.
    Wu, C.
    Mavrommatis, K.
    Beach, C. L.
    MacBeth, K. J.
    HAEMATOLOGICA, 2017, 102 : 39 - 39
  • [40] RESPONSE TO THALIDOMIDE AND CYCLOSPORINE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROME WITHOUT ISOLATED DEL(5Q)
    Wang, J.
    Qin, T.
    Xu, Z.
    Zhang, Y.
    Gale, R.
    Fang, L.
    Zhang, H.
    Pan, L.
    Hu, N.
    Qu, S.
    Li, B.
    Xiao, Z.
    LEUKEMIA RESEARCH, 2015, 39 : S127 - S127
12345